Rebecca A. Previs

Featured in: Favicon

tandfonline.com Favicon

aacrjournals.org Favicon

cancernetwork.com Favicon

cancerres.aacrjournals.org

Articles

"Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refrac" by Siqing Fu, Shuyang Yao et al.

Sep 16, 2024 | digitalcommons.library.tmc.edu | Siqing Fu |Shuyang Yao |Yuan Yuan |Rebecca A. Previs

PURPOSE: Preclinical cancer models harboringPATIENTS AND METHODS: Patients aged ≥ 18 years with measurable disease and refractory solid tumors harboringRESULTS: Thirty patients were enrolled. The median follow-up duration was 9.9 months.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →